Company intelligence / Profile preview
JJP Biologics
Warsaw, Mazowieckie, Polandjjpbiologics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
JJP Biologics has advanced its lead asset JJP‑1212—a first-in-class anti-CD89 monoclonal antibody—into a First-in-Human Phase I clinical trial targeting autoimmune and fibrotic diseases where pathogenic IgA plays a role. The company also received Orphan Drug Designation from the European Commission for this candidate. Its second asset targets HVEM/CD270 as an immune checkpoint inhibitor in oncology and remains at the preclinical stage. The company’s approach centers on integrating companion diagnostics to enable personalized treatment strategies.
- Therapeutic areas
- OncologyImmunologyDermatologyPulmonology
- Modalities
- Monoclonal antibodies (mAbs)Humanized antibodiesIgG4-kappa antibody (for JJP‑1212)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Financially backed by the Starak familyco-financed by Polish Medical Research Agency grants.Collaborates with universities and research centers across Poland.
Beyond the preview
Go deeper on JJP Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JJP Biologics.